Gyre Therapeutics Profit Margin

The latest profit margin for GYRE is -10.62% as of June 2026. That compares with 10.65% in the prior-year period — down 199.7% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Gyre Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GYRE's profit margin moved from 10.65% to -10.62% — a 199.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gyre Therapeutics's valuation or profitability profile.

Against Healthcare companies, GYRE currently prints -10.62% for profit margin, while the sector average sits near 13.89%. That is roughly 176.5% below the sector mean. Large gaps often invite a closer look at Gyre Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Gyre Therapeutics converts resources into returns. At -10.62%, GYRE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 10.65% in the prior-year period — down 199.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GYRE's profit margin (-10.62%), review year-over-year change from 10.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.